

# Nancy J Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1009541/publications.pdf>

Version: 2024-02-01

100  
papers

4,637  
citations

117625

34  
h-index

102487

66  
g-index

121  
all docs

121  
docs citations

121  
times ranked

6165  
citing authors

#	ARTICLE	IF	CITATIONS
1	Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*. Clinical Pharmacology and Therapeutics, 1996, 60, 8-13.	4.7	297
2	Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature Reviews Nephrology, 2013, 9, 459-469.	9.6	290
3	Aldosterone and end-organ damage. Current Opinion in Nephrology and Hypertension, 2005, 14, 235-241.	2.0	247
4	Aldosterone and Vascular Inflammation. Hypertension, 2008, 51, 161-167.	2.7	211
5	Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension, 2009, 54, 516-523.	2.7	200
6	High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery. JAMA - Journal of the American Medical Association, 2016, 315, 877.	7.4	200
7	Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation, 2016, 133, 1115-1124.	1.6	173
8	Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B <sub>2</sub> Receptor-Dependent, NO Synthase-Independent, and Cyclooxygenase-Independent Pathway. Circulation, 2000, 102, 2190-2196.	1.6	168
9	Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition. Circulation, 2001, 104, 839-844.	1.6	158
10	Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiological Reports, 2016, 4, e12780.	1.7	156
11	Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature. Hypertension, 1999, 33, 1431-1435.	2.7	147
12	Eplerenone. Circulation, 2003, 107, 2512-2518.	1.6	143
13	Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans. Hypertension, 2010, 56, 728-733.	2.7	137
14	Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin. Thrombosis and Haemostasis, 1997, 77, 522-525.	3.4	128
15	Possible Medication Errors in Home Healthcare Patients. Journal of the American Geriatrics Society, 2001, 49, 719-724.	2.6	125
16	Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. Hypertension, 2002, 39, 460-464.	2.7	106
17	The Vasculature in Prediabetes. Circulation Research, 2018, 122, 1135-1150.	4.5	91
18	ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism. Hypertension, 2002, 40, 859-865.	2.7	85

#	ARTICLE	IF	CITATIONS
19	Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 242-248.e2.	2.9	73
20	Human $\beta_2$ -adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 670-675.	4.7	70
21	Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 926-936.	4.5	68
22	Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition. <i>Hypertension</i> , 2014, 63, 951-957.	2.7	62
23	Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. <i>Kidney International</i> , 2011, 80, 978-985.	5.2	61
24	Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4533-4540.	3.6	61
25	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	2.4	48
26	The Renin-Angiotensin-Aldosterone System and Fibrinolysis in Progressive Renal Disease. <i>Seminars in Nephrology</i> , 2002, 22, 399-406.	1.6	44
27	Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 315-324.	2.1	43
28	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	43
29	Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 475-480.	2.3	42
30	Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0162753.	2.5	41
31	Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. <i>Pharmacoepidemiology and Drug Safety</i> , 1996, 5, 149-154.	1.9	39
32	Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. <i>Prostaglandins and Other Lipid Mediators</i> , 2014, 113-115, 38-44.	1.9	36
33	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004584.	2.2	36
34	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 483-495.	1.9	35
35	Interactive Effect of PAI-14G/5G Genotype and Salt Intake on PAI-1 Antigen. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1071-1077.	2.4	33
36	Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 163-168.	2.3	31

#	ARTICLE	IF	CITATIONS
37	A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1674-1681.	3.4	31
38	Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance. <i>Frontiers in Immunology</i> , 2019, 10, 408.	4.8	31
39	Dipeptidyl Peptidase 4 Inhibition and the Vascular Effects of Glucagon-Like Peptide-1 and Brain Natriuretic Peptide in the Human Forearm. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	28
40	Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 125, 2-7.	1.9	28
41	Preprescription Genotyping. <i>Circulation</i> , 2001, 103, 1608-1610.	1.6	27
42	Early urine electrolyte patterns in patients with acute heart failure. <i>ESC Heart Failure</i> , 2019, 6, 80-88.	3.1	27
43	Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 136-151.	3.6	27
44	American Heart Association Cardiovascular Genome-Phenome Study. <i>Circulation</i> , 2015, 131, 100-112.	1.6	26
45	Heart failure event definitions in drug trials in patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 294-296.	11.4	26
46	Dietary Sodium Restriction Decreases Insulin Secretion Without Affecting Insulin Sensitivity in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1895-E1902.	3.6	25
47	A pharmacodynamic interaction between caffeine and phenylpropanolamine. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 363-371.	4.7	24
48	Aldosterone and PAI-1: implications for renal injury. <i>Journal of Nephrology</i> , 2002, 15, 230-5.	2.0	22
49	Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	21
50	DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide) Tj ETQq0.0.0 rgBT /Overlock 1	2.7	21
51	Aprepitant for the Treatment of Pruritus in Sjögren Syndrome. <i>JAMA Dermatology</i> , 2018, 154, 1221.	4.1	19
52	Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. <i>PLoS ONE</i> , 2017, 12, e0175292.	2.5	19
53	Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis – a randomized cross-over study. <i>BMC Nephrology</i> , 2015, 16, 167.	1.8	18
54	Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. <i>Journal of the Endocrine Society</i> , 2017, 1, 1168-1178.	0.2	18

#	ARTICLE	IF	CITATIONS
55	Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1636-1639.e5.	2.9	18
56	Exome Sequencing Reveals Common and Rare Variants in <i>F5</i> Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1195-1202.	4.7	18
57	B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. <i>Chest</i> , 2016, 150, 102-111.	0.8	17
58	Hypertension Is Associated With Preamyloid Oligomers in Human Atrium: A Missing Link in Atrial Pathophysiology?. <i>Journal of the American Heart Association</i> , 2014, 3, e001384.	3.7	16
59	Transformation to academic leadership: The role of mentorship and executive coaching.. <i>Consulting Psychology Journal</i> , 2019, 71, 141-160.	0.8	16
60	Phenotype-Driven Plasma Biobanking Strategies and Methods. <i>Journal of Personalized Medicine</i> , 2015, 5, 140-152.	2.5	15
61	Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study. <i>BMJ Open</i> , 2018, 8, e021640.	1.9	15
62	Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 479-487.	2.5	13
63	Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 281-286.	4.4	13
64	Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. <i>Journal of the Endocrine Society</i> , 2019, 3, 1784-1798.	0.2	12
65	Developing Physician-Scientists. <i>Circulation Research</i> , 2018, 123, 645-647.	4.5	10
66	Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. <i>Analytical Chemistry</i> , 2020, 92, 859-866.	6.5	10
67	Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition. <i>Hypertension</i> , 2006, 47, 441-448.	2.7	9
68	Two Pools of Epoxyeicosatrienoic Acids in Humans. <i>Hypertension</i> , 2018, 71, 346-355.	2.7	9
69	GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans. <i>Hypertension</i> , 2021, 78, 1092-1102.	2.7	9
70	Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. <i>Journal of Cardiac Failure</i> , 2021, 27, 1231-1239.	1.7	8
71	This is not Dr. Conn's aldosterone anymore. <i>Transactions of the American Clinical and Climatological Association</i> , 2011, 122, 229-43.	0.5	8
72	Angiotensin II type I Receptor polymorphism in African Americans lower frequency of the C1166 variant. <i>IUBMB Life</i> , 1997, 43, 227-231.	3.4	7

#	ARTICLE	IF	CITATIONS
73	Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	7
74	Higher urinary cortisol levels associate with increased cardiovascular risk. <i>Endocrine Connections</i> , 2019, 8, 634-640.	1.9	7
75	DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. <i>Hypertension</i> , 2022, 79, 827-835.	2.7	6
76	Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. <i>BMJ Open</i> , 2020, 10, e033100.	1.9	5
77	Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population. <i>Global Heart</i> , 2017, 12, 133.	2.3	4
78	Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. <i>Hypertension</i> , 2016, 68, 549-551.	2.7	3
79	Developing physician-scientists: a perspective. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 218-29.	0.5	3
80	Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 662-668.	4.7	2
81	Statins to Reduce Acute Kidney Injury After Cardiac Surgery—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 349.	7.4	2
82	Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids. <i>Hypertension</i> , 2021, 77, 1323-1331.	2.7	2
83	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. <i>Hypertension</i> , 2021, 78, 376-386.	2.7	2
84	OR05-6 The Effect of the GLP1R Variant rs6923761 on Post-Prandial Glucose Levels during Treatment with Sitagliptin. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	2
85	Improving the medical record for clinical oncology research by adaptation to a microcomputer. <i>Medical and Pediatric Oncology</i> , 1983, 11, 352-357.	1.0	1
86	Mineralocorticoid Receptor Activation and Atrial Fibrosis. <i>Hypertension</i> , 2019, 73, 294-295.	2.7	1
87	MON-474 Dipeptidyl Peptidase-4 (DPP4) Inhibition Decreases Visceral Fat and Improves Glucose Metabolism in Overweight Women with Polycystic Ovarian Syndrome. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1
88	Loss of normal dietary sodium blood pressure response to angiotensin ii infusion in human essential hypertension. <i>American Journal of Hypertension</i> , 2004, 17, S159.	2.0	0
89	Response to Interleukin-6 Antagonists for the Management of Hypertension. <i>Hypertension</i> , 2007, 49, .	2.7	0
90	Patient-oriented Research in the Era of Personalized Medicine. <i>Clinical and Translational Science</i> , 2012, 5, 119-120.	3.1	0

#	ARTICLE	IF	CITATIONS
91	Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Nephrylsin Inhibition". Circulation, 2016, 134, e11-2.	1.6	0
92	MO045 MITOCHONDRIAL DYSFUNCTION AND MUSCLE ENERGETICS IN CKD PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
93	Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin". Journal of the Endocrine Society, 2020, 4, bvaa006.	0.2	0
94	Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. Hypertension, 2021, 77, 296-307.	2.7	0
95	Contribution of Coagulation Pathways and Fibrinolysis in Generation of Kinins.. Blood, 2006, 108, 1625-1625.	1.4	0
96	The Cardiovascular Effects of Peptidase Inhibition. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PL-3.	0.0	0
97	Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY39-3.	0.0	0
98	Muscle mitochondrial dysfunction at different stages of chronic kidney disease (CKD). FASEB Journal, 2018, 32, 908.2.	0.5	0
99	SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue. Journal of the Endocrine Society, 2020, 4, .	0.2	0
100	The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins and Other Lipid Mediators, 2022, 158, 106604.	1.9	0